Chest Medicine (all articles)
Observational study finds a single dose of either Pfizer-BioNTech and Oxford-AstraZeneca vaccines in older adults is about 80% effective at preventing admission to hospital with covid-19.
21 May, 2021 | 08:54h | UTCEditorial: Effectiveness of England’s initial vaccine roll out – The BMJ
M-A: Prevalence and outcomes of co-infection and superinfection with SARS-CoV-2 and other pathogens – The pooled prevalence of co-infection at the time of a SARS-CoV-2 diagnosis was 19%, and that of superinfection was 24%.
21 May, 2021 | 08:48h | UTC
Report: Face masks effectively limit the probability of SARS-CoV-2 transmission.
21 May, 2021 | 08:49h | UTCFace masks effectively limit the probability of SARS-CoV-2 transmission – Science
AARC Guideline: Management of adult patients with tracheostomy in the acute care setting.
21 May, 2021 | 08:26h | UTC
Cohort study: 14% of adults aged 65 years or less who were infected with SARS-CoV-2 had at least one new type of clinical sequelae that required medical care after the acute phase of the illness.
20 May, 2021 | 08:59h | UTCEditorial: Unpacking post-covid symptoms – The BMJ
Commentary on Twitter (thread – click for more)
After covid infections, 14% of >266,000 people, age ≤ 65, developed at least 1 sequelae that required medical care #LongCovid Just out @bmj_latest @OptumLabs @mlipsitch Risk increased w/ pre-existing conditions but also found in healthy, age < 50 https://t.co/h8IlnRNp2v pic.twitter.com/e15uSj9BXN
— Eric Topol (@EricTopol) May 19, 2021
FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination.
20 May, 2021 | 08:55h | UTC
Commentary on Twitter (thread – click for more)
Today, we issued a safety communication notifying the public and providers that results from SARS-CoV-2 antibody tests should not be used to evaluate immunity or protection from #COVID19 at any time – especially after receiving a #COVID19 vaccination. https://t.co/KlywV04WYO pic.twitter.com/TPdIVxWzSh
— U.S. FDA (@US_FDA) May 19, 2021
Systematic review and meta-analysis of observational studies suggest low-dose aspirin may be of benefit for patients with Covid-19 – the finds require further investigation in randomized studies.
20 May, 2021 | 08:54h | UTC
One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively
20 May, 2021 | 08:57h | UTCPrevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study – Lung
Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection
20 May, 2021 | 08:52h | UTCCommentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP
ERS clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years.
20 May, 2021 | 08:21h | UTC
[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.
19 May, 2021 | 08:51h | UTC
Commentary on Twitter (thread – click for more)
RECOVERY pre-print: Colchicine
11340 patients hospitalised with COVID-19
Randomised to colchicine vs usual care
No significant improvement in:
– 28-day mortality
– discharge alive at 28 days
– progression to invasive mechanical ventilation or deathhttps://t.co/mEtYq2qwkL pic.twitter.com/B0MNJWDi6e— Martin Landray (@MartinLandray) May 18, 2021
WHO Solidarity trial to restart with focus on drugs that act on immune responses caused by Covid-19.
19 May, 2021 | 08:47h | UTCInternational COVID-19 trial to restart with focus on immune responses – Nature
[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups.
18 May, 2021 | 08:04h | UTCTherapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv
Commentary on Twitter
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. https://t.co/TkhGs5qow5
— Ryan Zarychanski (@RZarychanski) May 17, 2021
#ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.
18 May, 2021 | 08:01h | UTCAntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology
Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD
COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.
18 May, 2021 | 07:56h | UTCCOVID vaccines can block variant hitting Asia, lab study finds – Nature
See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress
Commentary on Twitter
Pfizer & Moderna mRNA vaccines are effective against multiple SARSCoV2 variants, including the B.1.617 & B.1.618, 2 variants underlying the surge in India. The research, while not yet peer-reviewed, was conducted at NYU School of Medicine in New York City https://t.co/3ziRhk8f4t pic.twitter.com/VzYQKWqyQF
— delthia ricks ? (@DelthiaRicks) May 17, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
18 May, 2021 | 07:52h | UTC
M-A: Incidence and mortality of COVID‐19‐associated pulmonary aspergillosis – The incidence and mortality in the ICU were estimated to be 10.2% and 54.9%, respectively.
18 May, 2021 | 07:50h | UTC
Analysis: Where are we with drug treatments for covid-19?
18 May, 2021 | 07:47h | UTCWhere are we with drug treatments for covid-19? – The BMJ
Opinion | E-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth.
18 May, 2021 | 07:28h | UTCE-Cigarettes and the U.S. Menthol Ban: A Missed Opportunity to Protect Youth – Think Global Health
Commentary on Twitter (thread – click for more)
??? @US_FDA should ban flavors in all nicotine-containing products, not just menthol cigarettes. More than 8 out of 10 current youth e-cigarette users in the U.S. vape non-tobacco flavors.
IHME researchers for @ThinkGlobalHlth ?⤵️ https://t.co/d56mDCvTY3
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) May 17, 2021
Systematic review: Treatment of gastro-esophageal reflux disease to help manage asthma in adults and children may result in reduced use of rescue medications, but the benefits on the number of exacerbations and hospital utilization remain uncertain.
18 May, 2021 | 07:27h | UTC
RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.
17 May, 2021 | 08:56h | UTCInvited commentary: Convalescent plasma in patients hospitalised with COVID-19
Commentaries on Twitter
Convalescent plasma:
Yet another example of
Don’t guess, don’t gamble
Randomize… and learn
I’ve heard it said that it was deemed “too difficult” to do a randomised controlled trial. Really? If that’s the case, we must (and can) fix that problem. Pts deserve better. https://t.co/zxIiK5U63v
— Martin Landray (@MartinLandray) May 15, 2021
NEW #COVID19 research—In patients hospitalised with COVID-19, high-titre convalescent plasma did not improve survival or other prespecified clinical outcomes. Read https://t.co/7Sbe8V9THp. #RECOVERY #RECOVERYtrial pic.twitter.com/D0OLZKxZc4
— The Lancet (@TheLancet) May 16, 2021
[Preprint] Delaying second Pfizer vaccine dose to 12 weeks increases specific antibody response 3.5-fold in people over 80 years of age.
17 May, 2021 | 08:53h | UTCCommentaries: Delaying a COVID vaccine’s second dose boosts immune response – Nature AND Delaying Second Pfizer COVID-19 Vaccine Dose Increases Antibody Response Threefold In Over-80s, Study Finds – Health Policy Watch AND Delay in giving second jabs of Pfizer vaccine improves immunity – The Guardian AND Expert reaction to preprint looking at the immune response in older people after vaccination the Pfizer-BioNTech COVID-19 vaccine with either a 3-week or a 12-week dosing schedule – Science Media Centre
Modeling study: Delaying second doses of Pfizer-BioNTech and Moderna mRNA vaccines could reduce deaths by up to 20% under certain conditions.
17 May, 2021 | 08:51h | UTCCommentaries: Expert reaction to study looking at the public health impact of delaying the second dose of the Pfizer-BioNTech and Moderna COVID-19 vaccines – Science Media Centre AND Delaying second Covid vaccine doses can save lives, study finds – The Guardian AND Delaying second COVID vaccine dose may prevent deaths under certain conditions – The BMJ
#ACC21 – [Not published yet] RCT: DARE-19: Dapagliflozin is safe, but did not significantly improve outcomes among high-risk patients hospitalized with COVID-19.
17 May, 2021 | 08:49h | UTC
Commentaries on Twitter
DARE-19 trial #ACC21 @ACCinTouch
Dapa did not reduce clinical endpoints in #COVID19, but excellent safety profile
? Do not discontinue SGLT2i in ? for #COVID19
Full slideset available in ?https://t.co/RPi5mpPbbN pic.twitter.com/B9VQdSSAFu
— Enrique Santas (@SantasEnrique) May 16, 2021
DARE-19 findings presented at #ACC21 show #dapagliflozin didn’t significantly ⬇️ risk of organ failure or death or improve recovery in patients hospitalized w/ #COVID19. However, data suggest the SGLT2 inhibitor was well tolerated in acutely ill patients. https://t.co/YjYxbuc952 pic.twitter.com/J4PqwvGpLJ
— American College of Cardiology (@ACCinTouch) May 16, 2021
‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo.
17 May, 2021 | 08:45h | UTC‘It’s not over yet’: Uncertain protection from Covid vaccines leaves cancer patients in limbo – STAT